Bispecific LV20.19 CAR T Cells Induce 92% CR Rate in Relapsed/Refractory Mantle Cell Lymphoma

Bispecific LV20.19 CAR T Cells Induce 92% CR Rate in Relapsed/Refractory Mantle Cell Lymphoma - Blog

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy that researchers believe is not curable using current standard approaches. However, researchers developed a bispecific CAR T-cell therapy targeting both CD20 and CD19 cells induced a 92% complete response (CR) rate at 90 days in patients with relapsed/refractory MCL. In the study, researchers administered CAR T […]